rose bengal disodium + anti-PD-1 therapy + anti-CTLA-4 therapy

This is a **combination regimen** of three therapeutic modalities: - **Rose bengal disodium** is a synthetic xanthene dye functioning as a photosensitizer in photodynamic therapy and as an intralesional antineoplastic. Upon administration and irradiation, it directly induces apoptosis, necrosis, and immunogenic cell death in tumor cells, with evidence for activation of tumor-specific cytotoxic T-cell responses, likely due to the exposure and presentation of tumor antigens to the immune system[1][3][5]. - **Anti-PD-1 therapy** (e.g., pembrolizumab, nivolumab) consists of monoclonal antibodies that block the programmed cell death protein 1 (PD-1) checkpoint, sustaining effector T-cell activity and reversing tumor-induced immunosuppression, particularly in the effector phase of T-cell immunity[2][4]. - **Anti-CTLA-4 therapy** (e.g., ipilimumab) blocks the cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) checkpoint, broadening T-cell activation during the priming phase, lowering the activation threshold for anti-tumor T-cells, and enhancing immune responses[2][4]. In combination, these agents aim to maximize anti-tumor immune surveillance by generating immunogenic cell death (rose bengal disodium) and sustaining/augmenting T-cell mediated immune attack (anti-PD-1 and anti-CTLA-4), leading to synergistic anti-cancer efficacy, expanded T-cell repertoires, and potentially durable systemic responses[2][3][4]. This approach is under preclinical and early clinical investigation in settings such as metastatic melanoma and other solid tumors.